Reagent Kit for Determination of IgG Antibodies to the Receptor-Binding Domain (RBD) of the SARS-CoV-2 Spike Protein in Human Serum or Plasma via Solid-Phase Indirect ELISA

This reagent kit, “SARS-CoV-2 IgG RBD-IMBIAN-ELISA,” is designed for the quantitative detection of IgG antibodies to the RBD of the SARS-CoV-2 spike glycoprotein in human serum or plasma. Complies with TU-21.20.23-067-41390295-2021, Series № 21011 and Series № 21012.

Kit 1

Immunosorbent - 1 piece
Positive Control K(+) - inactivated, 1 vial (2.0 ml)
Negative Control K(-) - inactivated, 1 vial (2.0 ml)
Wash Solution Concentrate FSB-T (x26) - 1 vial (30.0 ml)
Buffer Solution BR - 2 vials (20.0 ml each)
Conjugate Concentrate KG (x20) - 1 vial (0.7 ml)
Substrate Solution PC - 1 vial (1.3 ml)
Chromogen Solution PX - 1 vial (13.0 ml)
Stop Reagent - 1 vial (20.0 ml)
Plate Sealing Films - 3 pieces
Pre-dilution Sample Plate - 1 piece
Reagent Kit User Manual - 1 copy

Kit 2

Immunosorbent - 1 piece
Positive Control K(+) - inactivated, 1 vial (2.0 ml)
Negative Control K(-) - inactivated, 1 vial (2.0 ml)
Wash Solution Concentrate FSB-T (x26) - 1 vial (30.0 ml)
Buffer Solution BR - 1 vial (20.0 ml)
Conjugate Solution RK - 1 vial (13.0 ml)
Tetramethylbenzidine (TMB) Solution - 1 vial (13.0 ml)
Stop Reagent - 1 vial (20.0 ml)
Plate Sealing Films - 3 pieces
Reagent Kit User Manual - 1 copy

If your organization wants to sell medical equipment, medical products or medical consumables in Russia, for example, Reagent Kit for Determination of IgG Antibodies to the Receptor-Binding Domain (RBD) of the SARS-CoV-2 Spike Protein in Human Serum or Plasma via Solid-Phase Indirect ELISA, then our information portal MEDCOMMERCE can help you with this. To do this, simply fill out the feedback form by clicking on the link FEEDBACK FORM.

The products posted on our website are approved for use in Russia by the state regulator Roszdravnadzor (Federal Service for Surveillance in Healthcare). The information is for informational purposes only.

Back